Compare Abeona Therapeutics Inc (ABEO) vs Global X FTSE Southeast Asia ETF (ASEA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Global X FTSE Southeast Asia ETF — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Global X FTSE Southeast Asia ETF trades at $20.21. Which is the better fit depends on your goals.
| ABEO | ASEA | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $20.65 |
52-Week Low | $4.17 | $16.25 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ASEA trades at $20.08, up 1.57% today, with technical indicators showing a bearish trend per moving averages while oscillators remain neutral. The stock faces resistance near $20 with support at $19. A dividend of $0.41 is scheduled for July 2026, but current financial ratios like P/E and P/S are unavailable, limiting fundamental clarity.
The outlook is cautious due to weak technical momentum and missing financial data. Risks include potential earnings volatility and market sentiment shifts. Investors should await updated SEC filings for valuation metrics before considering positions, as the bearish technical setup suggests near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →
